EFFECT OF THALIDOMIDE COMBINED WITH OXALIPLATIN AND PIRARUBICIN IN THE TREATMENT OF PRIMARY LIVER CANCER ON THE LEVELS OF TK1 AND CXCL13

SHAO ZEFENG¹, ZENG RONG¹, WANG GUOPIN², ZHANG CHENGJIA¹, BAI ZHUOJIE3^,

¹Department of Interventional Radiology, Nanjing Jiangbei People’s Hospital Affiliated of Nantong University, No.552 Geguan Road, Nanjing, Jiangsu, 210048, China - ²Department of Digestive, Nanjing Jiangbei People’s Hospital Affiliated of Nantong University, No.552 Geguan Road, Nanjing, Jiangsu, 210048, China - ³Department of Radiology, Nanjing Jiangbei People’s Hospital Affiliated of Nantong University, No.552 Geguan Road, Nanjing, Jiangsu, 210048, China

Objective: To investigate the efficacy of thalidomide combined with oxaliplatin and pirarubicin in the treatment of unresectable primary liver cancer with arterial chemoembolization (TACE) and the effects on TK1 and CXCL13 levels.

Methods: Eighty-five patients with primary liver cancer admitted to our hospital from January 2015 to January 2018 were selec- ted. The patients were divided into the control group (43 cases) and the observation group (42 cases) according to the TACE treatment plan. The control group was treated with fluorourea combined with oxaliplatin and pirarubicin. The observation group was treated with thalidomide combined with oxaliplatin and pirarubicin.

Results: The total effective rate of the observation group was 33.33%, and the disease control rate was 88.10%, which were signi- ficantly higher than those of the control group (13.95% and 65.12% (χ2=4.44, P=0.035, χ2=6.24, P=0.013), respectively). The inciden- ce of adverse reactions in the observation group was 33.33%, which was significantly lower than the 58.14% incidence of the control group (χ2=5.27, P=0.022). After treatment, the levels of TK1 and CXCL13 in the observation group were 8.40 ± 1.21 pmol/L and 45.69 ± 5.71 pmol/L, respectively, which were significantly lower than those of the control group (13.66 ± 2.71 pmol/L and 52.33 ± 8.81 pg/mL, respectively (both P < 0.05)).

Conclusion: Thalidomide combined with oxaliplatin and pirarubicin is effective and safe in the treatment of unresectable primary liver cancer, and it can reduce the levels of TK1 and CXCL13.